Combining 21 trials evaluating lipid outcomes , fish oil consumption result ed in a summary net change in triglycerides of -27 ( 95 % CI -33 , -20)mg/dL , in HDL cholesterol of + 1.6 ( 95 % CI + 0.8 , + 2.3)mg/dL , and in LDL cholesterol of + 6 ( 95 % CI + 3 , + 8)mg/dL. There was no effect of fish oil on total cholesterol .
Across studies , higher fish oil dose and higher baseline levels were associated with greater reductions in serum triglycerides .
The evidence supports a dose-dependent beneficial effect of fish oil on serum triglycerides , particularly among people with more elevated levels .
Fish oil consumption also modestly improves HDL cholesterol , increases LDL cholesterol levels , but does not appear to adversely affect glucose homeostasis .
The evidence regarding the effects of omega-3 fatty acids on hs-CRP is inconclusive , as are data on ALA
Greater fish oil consumption has been associated with reduced CVD risk , although the mechanisms are unclear .
Plant- source oil omega-3 fatty acids ( ALA ) have also been studied regarding their cardiovascular effect .
Effect of marine oils supplementation on coagulation and cellular activation in whole blood
A study was performed to explore the effects of supplemental intake of various marine oils known to be part of the Eskimo diet . Healthy men and women ( 134 ) were r and omly selected to consume 15 mL/d of oil from blubber of seal , cod liver , seal/cod liver , blubber of Minke whale , or no oil for ten weeks . Total cholesterol was unchanged in the oil groups , whereas high density lipoprotein cholesterol increased 7 % in the seal/cod liver oil ( CLO ) group ( P<0.05 ) and 11 % in the whale oil group ( P<0.005 ) . Triacylglycerol was significantly reduced in the CLO group only . The concentration of prothrombin fragment 1 + 2 was reduced 25 % ( P<0.05 ) after whale oil supplementation . No change in fibrinogen or factor VIIc was detected . Tumor necrosis factor generation in lipopolysaccharide (LPS)-stimulated blood was 30 % reduced after whale oil ( P<0.05 ) , but was unaffected by intake of seal or CLO . The LPS-induced tissue factor activity in monocytes was reduced to a significant degree only in the seal/CLO group ( 34 % ) and whale oil group ( 35 % ) ( P<0.05 ) . The most dramatic change in thromboxane B2 in LPS-stimulated blood was seen after whale oil intake with 44 % reduction ( P<0.01 ) . Supplementation of a regular diet with a combination of seal oil and CLO and especially with whale oil seems to have beneficial effects on several products thought to be associated with cardiovascular and thrombotic diseases
Combining 21 trials evaluating lipid outcomes , fish oil consumption result ed in a summary net change in triglycerides of -27 ( 95 % CI -33 , -20)mg/dL , in HDL cholesterol of + 1.6 ( 95 % CI + 0.8 , + 2.3)mg/dL , and in LDL cholesterol of + 6 ( 95 % CI + 3 , + 8)mg/dL. There was no effect of fish oil on total cholesterol .
Across studies , higher fish oil dose and higher baseline levels were associated with greater reductions in serum triglycerides .
The evidence supports a dose-dependent beneficial effect of fish oil on serum triglycerides , particularly among people with more elevated levels .
Fish oil consumption also modestly improves HDL cholesterol , increases LDL cholesterol levels , but does not appear to adversely affect glucose homeostasis .
The evidence regarding the effects of omega-3 fatty acids on hs-CRP is inconclusive , as are data on ALA
Greater fish oil consumption has been associated with reduced CVD risk , although the mechanisms are unclear .
Plant- source oil omega-3 fatty acids ( ALA ) have also been studied regarding their cardiovascular effect .